相关实验视频
Updated: Jul 14, 2025

06:00
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
234
抗糖尿病甲福明的抗焦虑作用是由mPFC抑制神经元中的AMPK激活介导的
Yong-Mei Zhang1,2,3, Hai-Chao Zong1,3, Ying-Bei Qi1,2,3
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Molecular psychiatry
|October 5, 2023
概括
甲福明是一种抗糖尿病药物,可以通过在中间前额叶皮层 (mPFC) 中激活AMPK来治疗焦虑. 这种激活恢复GABAergic抑制,减少小鼠的焦虑类行为.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 一种常见的抗糖尿病药物梅特福林与患者的焦虑减轻有关,但根本机制尚不清楚.
- 焦虑症与特定的神经生物学变化有关,包括大脑活动和神经传递的改变.
研究的目的:
- 研究AMP激活蛋白激酶 (AMPK) 在中部前额皮层 (mPFC) 在焦虑类行为中的作用.
- 阐明甲双对抗焦虑效应的机制,重点关注AMPK和GABAergic信号传递.
主要方法:
- 使用了转基因小鼠模型,具有脑特异性和GABAergic神经元特异性的AMPK淘汰.
- 服用甲胺并使用基因操纵 (过度表达/绝杀) 来调节mPFC中的AMPK活性.
- 进行了电生理学记录 (大脑切片),以评估mPFC金字塔神经元中的GABAergic传输.
- 使用已建立的行为范式评估类似焦虑的行为.
主要成果:
- 焦虑诱导导致mPFC的特定区域AMPK减少,与焦虑类行为相关联.
- 甲胺治疗或AMPK过度表达使mPFCAMPK活性正常化,并减轻焦虑.
- 在mPFC中AMPK的遗传删除引起了焦虑,并阻止了甲福林的抗焦虑作用.
- 甲胺和AMPK激活恢复了GABAergic抑制传播,并纠正了mPFC中的激发-抑制不平衡.
结论:
- 在mPFC抑制神经元内AMPK激活是甲福林抗焦虑作用的关键机制.
- 甲胺的治疗潜力超越了糖尿病,这表明它在治疗焦虑障碍方面的有用性.
- 在mPFC的GABAergic系统中准AMPK为焦虑提供了一个新的治疗策略.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
215
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
215
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Dipeptidyl Peptidase 4 Inhibitors
196
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
196
Regulation of Food Intake
258
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
258
GPCRs Regulate Adenylyl Cylase Activity
5.6K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.6K
Glucagon-like Receptor Agonists
337
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
337

